CLL-1/CD33 Targeted LCAR-AMDR Cells（Nanjing Legend Biotechnology）

CLL-1/CD33靶向 LCAR-AMDR 细胞（南京传奇生物）

Report date: 2024/11/27 20:00:40

Base Information

Drug NameCLL-1/CD33 Targeted LCAR-AMDR Cells（Nanjing Legend Biotechnology）
Drug Alias NameN/A
ClassificationCell and gene therapy > Cell therapy
Mechanisms of ActionMyeloid cell surface antigen CD33 modulatorsC-Type lectin domain family 12 member A modulators
TargetsMyeloid cell surface antigen CD33C-Type lectin domain family 12 member A
Therapy Area/IndicationsLeukemia, Myeloid, Acute
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryMainland China
CombinationsNo
Global Highest StatusDiscontinued (Phase 1 Clinical)
Highest Status in ChinaDiscontinued
Originator CompaniesNanjing Legend Biotechnology Co Ltd
China Registration ClassN/A

Develop Information

Active CompaniesN/A
Inactive CompaniesNanjing Legend Biotechnology Co Ltd
Active IndicationsN/A
Inactive IndicationsLeukemia, Myeloid, Acute

Other Information

ATC CodeN/A
Related LinksN/A